Highlights in IO: next-generation CAR-T therapy for glioblastoma - PubMed
21 hours ago
- #Immunotherapy
- #CAR-T therapy
- #Glioblastoma
- Phase 1 clinical trials of CAR-T cell therapies for glioblastoma (GBM) have been reported.
- Challenges for CAR-T therapy in GBM include immunosuppressive microenvironment, antigen heterogeneity, and anatomical isolation.
- Next-generation CAR-T cells with additional functionalities are being developed and tested in phase 1 trials.
- Antitumor efficacy needs improvement, and neurotoxicity remains a major issue.
- There is growing anticipation that next-generation CAR-T therapies may benefit patients.